ReviewACS infectious diseases2026
Natural and Synthetic AMPs from Latin America across Diversity Engineering and Applications.
Review in ACS infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Latin America's biodiversity accounts for approximately 60% of the world's total, fueling scientific research into natural products, a highly relevant area in drug discovery to this day. This is accompanied by an increasing number of antimicrobial peptides (AMPs) derived from natural products in the region, which over the past decade have been redesigned through modifications, enhancements, and refinements of their physicochemical properties and antimicrobial potency, using approaches that range from rational design and structure-activity relationship (SAR) studies to artificial intelligence and machine learning methodologies. AMPs and their derivatives represent a vast chemical space with potential for antibacterial, antifungal, antiviral, and antiparasitic therapies, with emerging applications beyond infectious diseases. Over the years, studies have identified these peptides from a wide range of sources, including amphibians, reptiles, invertebrates, and microorganisms from South America, highlighting their diverse biological activities. This raises important questions about whether Latin America is a fertile source of inspiration for the development of AMPs. It also prompts an examination of the region's historical and ongoing contributions to the field of natural and synthetic AMPs with anti-infective potential. Additionally, it highlights the need to assess the region's progress in keeping pace with the recent advancements in engineering AMPs to combat resistant bacteria. This mini-review addresses these topics and related issues, exploring Latin America's discoveries, challenges, and innovations in AMPs and their applications, particularly in anti-infective agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.